Background. Gastric cancer is one of the most common cancers in Japan. The use of endoscopy is increasing, along with the number of histological examinations of specimens obtained by endoscopy. However, it takes several days to reach a diagnosis, which increases the medical expense. Raman spectroscopy is one of the available optical techniques, and the Raman spectrum for each molecule and tissue is characteristic and specifi c. The present study investigated whether Raman spectroscopy can be used to diagnose gastric cancer. Methods. A total of 251 fresh biopsy specimens of gastric carcinoma and non-neoplastic mucosa were obtained from 49 gastric cancer patients at endoscopy. Without any pretreatment, the fresh specimens were measured with a near-infrared multichannel Raman spectroscopic system with an excitation wavelength of 1064 nm, and Raman spectra specifi c for the specimens were obtained. A principal component analysis (PCA) was performed to distinguish gastric cancer and nonneoplastic tissue, and a discriminant analysis was used to evaluate the accuracy of the gastric cancer diagnosis. Results. The Raman spectra for cancer specimens differed from those for non-neoplastic specimens, especially at around 1644 cm −1
Introduction
Gastric cancer is one of the most common cancers in Japan. Each year, about 50 000 new cases of gastric cancer are diagnosed, and about 50 000 people die from the disease. Since the rate of early gastric cancer detection is increasing, 5-year survival after curative surgery for gastric cancer has reached more than 70%. The development of endoscopy has contributed to the detection of early gastric cancer and improved the prognosis of such patients. Every year, the number of people who receive endoscopy instead of an upper gastrointestinal series as part of a routine examination is increasing. Although histological examination of biopsied specimens is one of the advantages of endoscopy, it increases the medical expense and usually takes several days for preparation of the specimens.
Recently, many efforts have been made toward establishing endoscopic diagnostic techniques that utilize advanced optical techniques. The optical techniques applied to endoscopy are point spectroscopy, high-resolution endoscopy, magnifi cation endoscopy, chromoendoscopy, autofl uorescence endoscopy, narrow-band imaging, and coherence tomography. Point spectroscopy is based on the analysis of specifi c light-tissue interactions that contain diagnostic information about the structural or molecular composition of the tissue.
detect. Recent technical developments, such as lasers, optical electronics, and computers, have been investigated for enabling clinical application of RAS.
RAS is a technique that detects Raman scattering, that is, inelastic scattered light that has undergone a small shift in wavelength called the Raman shift. In this process, photons incident on a sample transfer energy to or from molecular vibrational modes. 2 Specifi cally, a coherent two-photon process occurs in which a molecule simultaneously absorbs an incident photon and emits a Raman photon, accompanied by its transition from one energy level to another, thereby giving rise to a frequency (i.e., energy) shift of the emitted photon. Individual bands in the Raman spectrum are characteristic of specifi c molecular motions because the energy levels are unique for every molecule.
RAS is especially suitable for in vivo measurements, since the excitation light energy does not affect the tissue and the penetration depth is relatively large. 4 Furthermore, RAS has the superior advantages of objectivity, simplicity (preliminary treatment is not required), minimal invasiveness, and rapidity. In addition, Raman spectra provide detailed chemical information about a tissue sample, thereby allowing insights into the chemical changes that accompany gastric cancer.
During RAS assessment, it is crucial to prevent any infl uence of fl uorescence. Since the signal magnitude of Raman scattering is extremely weak compared to that of fl uorescence, Raman scattering may be masked by strong autofl uorescence from the tissue. In the present study, we used a method involving excitation by long-wavelength near-infrared light to prevent any interference by fl uorescence. The Raman shift stays constant regardless of the wavelength of the excitation light and is therefore specifi c for the tissue. In other words, data from a Raman spectrum do not change even when long-wavelength excitation is used. Therefore, a pure and true Raman spectrum can be obtained by long-wavelength excitation light without any interference from fl uorescence. Since Raman scattering of long-wavelength excitation light is not detected by a common CCD, we developed a near-infrared multichannel RAS system with sensitivity to wavelengths up to 1400 nm. By using our novel Raman diagnostic system, the infl uence of autofl uorescence can be removed and weak Raman scattering originating from the cancer tissue can be detected. Furthermore, we can distinguish differences in the spectra originating from cancer and non-neoplastic tissues (i.e., normal mucosa).
The aim of the present study was to investigate whether RAS can be applied to the diagnosis of gastric cancer, especially during endoscopy. We obtained ex vivo specimens during endoscopy and examined them with our novel Raman diagnostic system.
Materials and methods

Patient and samples
Fresh biopsy specimens of primary gastric carcinoma and non-neoplastic mucosa were obtained from 49 gastric cancer patients who underwent an endoscopic examination at the Second Department of Surgery, Hamamatsu University School of Medicine, from January 2005 to June 2006. Ethical approval for the study was obtained from the Institutional Review Board, and all the patients provided written informed consent. A total of six biopsy specimens were obtained from each patient, of which three were from the gastric carcinoma and three were from the non-neoplastic mucosa. Regarding the three non-neoplastic samples, one was obtained from the upper third of the stomach, one from the middle third, and one from the lower third.
The subjects comprised 38 men and 11 women, with a mean age of 61.8 (range, 31-81) years. None of the patients had received chemotherapy, radiotherapy, or immunomodulatory agents before the endoscopic examination. Among the 49 patients, the tumor location was in the upper third of the stomach in eight (16.3%), the middle third in 19 (38.8%), and the lower third in 22 (44.9%). The histological type was categorized as papillary adenocarcinoma (pap), tubular adenocarcinoma (tub1 + tub2), poorly differentiated adenocarcinoma (por1 + por2), signet ring cell carcinoma (sig), or mucinous adenocarcinoma (muc) according to the Japanese Classifi cation of Gastric Carcinoma of the Japanese Gastric Cancer Association. 5 Other clinical fi ndings of the 49 patients are shown in Table 1 .
The fresh samples were immediately placed in plastic tubes without any treatment and stored on ice until analysis.
Finally, we measured Raman spectra of a resected gastric cancer specimen with the patient's written informed consent and Institutional Review Board approval. Raman spectra were measured at several points of the gastric mucosa, in both cancerous and nonneoplastic regions, immediately after resection.
Near-infrared RAS system with a 1064-nm excitation wavelength
We used a near-infrared multichannel RAS system ( Fig.  1) . A Nd:YAG laser (1064 nm; repetition rate, 10 kHz; pulse width, 10 ns; average power, 100 mW at the sample point) was used for excitation. In order to visualize the Raman sampling spot, a He-Ne laser beam (power, ∼10 mW) was overlapped with the 1064-nm beam. The Nd:YAG laser beam was focused on a 0.1-mm (i.d.) sample area. The backscattered light from the sample was collected by an achromatic lens (f = 45 mm), focused tering and room light. The exposure time was 1 s. The spectrum was obtained 400 times, and then the spectra were averaged at each sampling point. All measurements were made in the wave number range of 950 to 1800 cm −1 , and background was subtracted from each spectrum.
Assessment of RAS
Each biopsy specimen was placed in a 2-mm-diameter hole in an aluminum block and measured four times, changing the measurement point each time, using the near-infrared multichannel RAS system described above.
After the experiment, each tissue sample was used to create a hematoxylin and eosin (HE)-stained specimen, and the tissue diagnosis was confi rmed histologically.
The obtained Raman spectrum was subjected to sensitivity corrections using the spectral data of white light and wavelength corrections using the Raman spectral data of indene. The corrected spectrum was standardized by the total intensity of the area in the range of 1027.5-1794 cm
. The standardized Raman spectra obtained from the measurement points of one specimen were averaged into one spectrum, which was specifi c for the biopsy specimen. The averaged spectrum was used for further analyses.
Data analysis
The spectral data were processed and analyzed with the Unscrambler Version 9.6 software package (Camo Technologies, Woodbridge, NJ, USA) and Systat Version 11 (Systat Software, San Jose, CA, USA). A principal component analysis (PCA), a multivariate analysis method, can be used to extract and express the features of Raman spectra that have a lot of information specifi c to each sample, allowing discrimination of spectrum data. We performed PCA of the Raman spectra to distinguish gastric cancer tissue and non-neoplastic tissue and a discriminant analysis to evaluate the accuracy of the gastric cancer diagnosis obtained by using the 1064-nm excitation wavelength multichannel RAS system.
In addition, we performed t tests to analyze the signifi cance of differences between cancer and non-neoplastic tissues at a single intensity of the Raman shift, namely the 1644 cm −1 band.
Results
Substance diagnosis using RAS
To confi rm the utility of the 1064-nm excitation wavelength near-infrared multichannel RAS system as a sub- by another lens (f = 100 mm) on the entrance slit of a polychromator, and detected by a newly developed near-infrared gated image intensifi er with an InP/ InGaAsP photocathode (Hamamatsu Photonics, Shizuoka, Japan) and photo diode array (480 effective channels). In order to eliminate thermal noise and contamination by room light, the multichannel detector was gated (gate width, 100 ns) and synchronized with the Nd:YAG laser pulse (10 kHz). Two holographic notch fi lters and a silicon fi lter were used to avoid laser scat-stance diagnosis tool, we measured the Raman spectra of human blood and human fat tissue with our novel RAS system. The blood sample was obtained from one of the researchers of the present study, while the human fat tissue sample was obtained from intra-abdominal fat during an operation for gastric cancer with the patient's written informed consent and Institutional Review Board approval. As shown in Fig. 2a and b, Raman spectra with high signal-to-noise ratio were measured following 1064-nm excitation, and each spectrum appeared to have several clear peaks. The main peak positions of the Raman spectra obtained for blood and fat tissue were at 1560 cm −1 and 1450 cm
, respectively, and their overall patterns appeared to be very different.
Next, we measured non-neoplastic biopsy samples with a conventional RAS system with a 785-nm excitation wavelength (HoloLab-5000-785, Kaiser Optical Systems, Ann Arbor, MI, USA) to confi rm the usefulness of long-wavelength (1064-nm) excitation (Fig. 2c) . In the conventional RAS system, Raman features were masked by the strong autofl uorescence background, although our RAS system detected a Raman spectrum of the gastric mucosa with a high signal-to-noise ratio (Fig. 3) .
These fi ndings suggest that the 1064-nm excitation wavelength near-infrared multichannel RAS system is a useful tool for substance diagnosis, similar to other previously used RAS systems.
Cancer diagnosis using RAS
We measured the Raman spectra of 251 (123 cancer and 128 non-neoplastic) biopsy specimens obtained from 49 gastric cancer patients using the 1064-nm near-infrared multichannel RAS system. As shown in Fig. 3a , the overall patterns of the Raman spectra obtained from cancer and non-neoplastic specimens were similar. However, the averaged Raman spectra for the cancer specimens could be distinguished from those for the non-neoplastic specimens (Fig. 3b) . These fi ndings suggest that the 1064-nm excitation wavelength near- Fig. 2a-c . Typical Raman spectrum patterns for (a) blood and (b) fat tissue. These high signal-to-noise ratio Raman spectra measured after excitation at 1064 nm appear very different. c Raman spectra of non-neoplastic biopsy samples made with a conventional Raman spectroscopy system (785-nm excitation) infrared multichannel RAS system has the potential to become a novel tool for the diagnosis of gastric cancer.
We performed PCA and discriminant analysis of the Raman spectra obtained from the 251 specimens to further refi ne the above-described results. As shown in Table 2 , 81 of 123 cancer specimens confi rmed pathologically were diagnosed as "carcinoma" (sensitivity, 66%), and 94 of 128 non-neoplastic specimens were diagnosed as "non-carcinoma" (specifi city, 73%). The accuracy of diagnosis using the 1064-nm excitation wavelength near-infrared multichannel RAS system, obtained by PCA, was 70% (Table 2) . Figure 4a shows the fi rst principal component of all Raman spectra from the gastric mucosa biopsies. The wave number of the highest peak of the fi rst principal ing that these specimens showed a characteristic behavior at this wave number. To simplify the diagnostic criteria and materials, we evaluated the possibility of using only the single intensity of the Raman shift at 1644 cm −1 . The intensities of all spectra at 1644 cm −1 are shown in Fig. 4b . Signifi cant differences were detected between the cancer and non-neoplastic specimens (P < 0.001; Fig. 4b ). As shown in Table 3 , 86 of 123 cancer specimens were diagnosed as "carcinoma" (sensitivity, 70%) and 89 of 128 non-neoplastic specimens were diagnosed as "non-carcinoma" (specifi city, 70%). The accuracy of diagnosis using the single intensity of the Raman shift at 1644 cm −1 was 70% (Table 3) , consistent with the above-described result obtained by PCA.
Cancer diagnosis using a single intensity of the Raman shift at 1644 cm
−1
Raman spectra of the resected specimen
Raman spectra were obtained from fi ve measurement points in the cancer region and fi ve points in the nonneoplastic region of the resected specimen. As shown in Fig. 5 , the Raman spectra of the cancer region were distinguishable from those of the non-neoplastic region. The intensity of the Raman shift at 1644 cm −1 in the cancer region was signifi cantly different from that in the non-neoplastic region in this specimen (t test; P < 0.05).
Discussion
The goal of the present study was to establish a realtime RAS diagnostic system for gastric cancer, since this type of cancer is the most common malignancy in Japan and a novel diagnostic system would be benefi cial for both patients and physicians. For instance, endoscopy with RAS has the potential to become a novel tool for real-time diagnosis, which would enable immediate determination of the optimal modality of treatment for gastric cancer and improve patient morbidity. Regarding gastric cancer, RAS has previously only been examined in vitro; the present study was the fi rst to use RAS for fresh clinical speciments. 6, 7 Although RAS methods remain to be standardized with regard to not only the preparation of specimens but also the excitation wavelength, RAS has previously been used for various malignancies, including those of the breast, [8] [9] [10] [11] [12] [13] [14] skin, 15 lung, [16] [17] [18] oral cavity, 19, 20 cervix, [21] [22] [23] [24] esophagus, [25] [26] [27] [28] colorectum, 29, 30 gynecological tract, 31 bladder, 32 prostate gland, 32, 33 and other. 6, 25 Among these malignancies, RAS of breast cancer was reported to have high specifi city and sensitivity in an ex vivo study, and the usefulness of its clinical application at mastectomy was recently reported. 9 Compared with the interesting results of RAS for breast cancer, gastric cancer has some diffi culties regarding RAS assessment for three reasons. First, a welldeveloped cancer becomes dense and hard in breast cancer, whereas these changes are not characteristic in gastric cancer, suggesting that the compositions of proteins or other molecules specifi c for breast cancer tissues are not as abundant in gastric cancer. Second, gastric cancers comprise various histological types that have different Raman spectra. Furthermore, differential diagnosis between cancer and adenomatous change is not easy, even for pathologists. We observed a difference in Raman spectra between tubular adenocarcinoma and poorly differentiated adenocarcinoma. However, further investigations are needed to clarify the characteristic Raman spectra according to histological type. Third, chronic infl ammation is almost always present in the non-neoplastic gastric mucosa of gastric cancer patients.
To overcome the diffi culties of RAS in gastric cancer, we developed a novel RAS system with high sensitivity. Furthermore, the excitation light wavelength in our RAS system was set at 1064 nm to exclude any effect of fl uorescence emitted from the gastric mucosal tissues, since gastric mucosa have been reported to emit strong fl uorescence 1, 34, 35 and the Raman scattering is expected to be extremely weak compared with the fl uorescence.
Some previous studies support our experimental design. 12, 16, 36, 37 Min et al. 16 reported that they could not identify a recognizable Raman band when an excitation wavelength of 785 nm was used because the strong fl uorescent background masked the Raman features. They also mentioned that they could measure a Raman spectrum with high signal-to-noise ratio without diffi culty after excitation at 1064 nm. Meanwhile, Yamazaki et al. 17 analyzed Raman spectra after excitation at 1064 nm, obtaining 210 spectra for 105 normal tissues and 105 cancer tissues from 35 patients with lung cancer, and found a sensitivity of 91% and specifi city of 97%. Min et al. also reported that a clear distinction could be made after excitation at 1064 nm between normal and cancerous states of fresh lung tissue samples obtained from 35 lung cancer patients undergoing a surgical procedure. 16 Although we found that RAS is a potential diagnostic tool for gastric cancer, our results are still unsatisfactory; increases in both sensitivity and specifi city are essential for establishing RAS as a novel diagnostic tool. Both the method of assessment and the RAS instruments need be improved for clinical application. We are currently investigating the Raman spectra of normal tissues. With written informed consent from patients and Institutional Review Board approval, we have just started to investigate Raman spectra of normal specimens from the patients without Helicobacter pylori infection or gastritis in order to establish the standard Raman spectra of normal gastric mucosa. In addition, we have focused our attention on using the single intensity of the Raman shift at 1644 cm . The accuracy of diagnosis using this single intensity as well as the result from the PCA using information for all spectra was established in the present study, and this analysis represents a very easy method for diagnosing gastric cancer. The use of a single intensity may allow simplifi cation of the Raman diagnostic system, including the RAS mechanical method, as well as continuous improvements in the analysis method.
For clinical applications, the RAS system needs to be more compact and simple. Furthermore, the development of an endoscopic probe is essential for endoscopy with RAS. Shim et al. 25 demonstrated the feasibility of using RAS in vivo during routine clinical gastrointestinal endoscopy of the esophagus and colon mucosa, but did not achieve a clinical diagnosis. We are currently working on a foundation study for the development of an endoscopic probe for RAS.
RAS has additional potential compared with other optical techniques. It is often referred to as "molecular fi ngerprinting," because it relies on extracting chemical information from samples based on their molecule-specifi c Raman spectra, which result from the molecular vibrations excited by the incident monochromic light. It is possible that RAS reveals cancer-specifi c molecules in specifi c Raman bands. Min et al. 16 observed that the intensity of the 1659 cm −1 band was markedly increased in lung cancer tissues after excitation at 1064 nm. The 1659 cm −1 band results from the amide I vibration, and changes in the protein concentration are the most likely cause of increases in the amide I band intensity in cancer tissues. In the present study, we could not identify spe- band may be the Raman band of some molecular component that is increasing and specifi c to gastric cancer, and if this is the case, it is may be possible to identify that molecule.
We have just started to measure the Raman spectra of gastric mucosa obtained from specimens after surgery for gastric cancer. Raman spectra in the cancer region were distinguishable from those in non-neoplastic region. However, we need to investigate Raman spectra in greater detail, including by comparing the Raman spectra of surgical specimens with those of biopsied specimens.
In conclusion, the present study is the fi rst to indicate the feasibility of gastric cancer diagnosis by using a 1064-nm excitation wavelength infrared multichannel RAS system. If such a Raman diagnostic system for gastric cancer becomes established, it will improve the clinical diagnosis of gastric cancer and be benefi cial for patients. This is the fi rst step for future studies and applications of RAS to optical biopsy and diagnosis of gastric cancer.
